šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM Ā· Real-Time Price Ā· USD
92.49
+0.54 (0.59%)
At close: Nov 18, 2026, 4:00 PM EST
92.60
+0.11 (0.12%)
After-hours: Nov 18, 2026, 4:32 PM EST
← View all transcripts

8th Annual Wolfe Research Healthcare Conference

Nov 10, 2026

Summary

Five regulatory filings are expected in 2027, with multiple approvals targeted within 18 months. Growth spans LIVMARLI, biliary atresia, volixibat and HDV; brelovitug’s BLA is on track for H1 2027, and positive cash flow is expected in 2027.

Kalpit Patel
Analyst, Wolfe Research

Okay. Welcome to day two of the Wolfe Healthcare Conference. I'm Kalpit Patel. I'm pleased to have here with me the team from Mirum, Andrew and Eric. Welcome, and thank you for joining us. Eric, it's been a pretty eventful few months for Mirum in recent times. You've had some positive clinical readouts, launched another commercial medicine, and raised revenue guidance again. Maybe to kick us off, what should we look out over the next 12-18 months, and what do you think investors are still underappreciating about where the business is heading?

Eric Bjerkholt
CFO, Mirum

Thank you, Kalpit, and first of all, thank you to Wolfe Research for hosting us, and let me remind you that we will be making forward-looking statements, so please look at the risk factors in our regulatory filings. I think it's often investors like to focus down on the details as they should, and really on the news of the day and maybe comparing to other programs, etc . When you do that, it's often easy to lose view of the overall picture. So let me remind you that less than 5% of orphan diseases have an FDA-approved medicine, and we are trying to change that by bringing to market medicines that have a profound positive impact on patients' lives.

To date, we have four approved medicines with many more to come. Based on all the successes in the clinic we've seen this year, we expect five sNDA, NDA, and BLA filings next year. W ithin 18 months, we should have many more medicines approved and indications approved. With that, we expect very significant revenue growth over the next 5+ years, resulting in very significant cash flow generation. I think when you focus too much on the details, you lose track of the overall picture and where we are headed.

Kalpit Patel
Analyst, Wolfe Research

Got it. Okay, and I want to start with LIVMARLI first, which continues to drive a lot of commercial momentum. You reported about $133 million in third-quarter sales, and you've talked about sustaining that to $10 million-$15 million roughly in sequential quarterly growth over the next year. How much of that is coming from newly diagnosed adult PFIC patients versus deeper penetration of the existing population, or just weight-based dose increases that you would expect as you go into the adult PFIC population?

Eric Bjerkholt
CFO, Mirum

Yeah, thank you. They are all elements. Alagille is growing steadily quarter-over-quarter. We keep adding new patients. We keep anchoring on being about 50% penetrated of the treatment-eligible population. Clearly, the big grower is PFIC, where we think it is early days still. We are adding a lot of patients. They are dosed twice a day compared to Alagille, which is daily dosing, and they tend to be older and therefore heavier and consume more drugs. So that clearly drives the revenue growth, and we think we have a long way to go, which is why we came out with this expectation that our sequential increases of $10 million-$15 million should continue for the foreseeable future.

Kalpit Patel
Analyst, Wolfe Research

Okay. And what are you learning about how quickly these patients can be found or diagnosed and brought onto therapy?

Eric Bjerkholt
CFO, Mirum

Yeah, I think genetic testing is very common amongst pediatric hepatologists, but much less so amongst adult hepatologists and GI docs and so w e are out there trying to educate that community on the importance of genetic testing, and that leads to a number of these patients being found. So, it is work, but it is work we are doing, and it is very successful and w e are also not the only ones doing it, right? We do have a competitor, and I think in PFIC, we are probably splitting the opportunity more or less. And so between the two of us, I think we are making a lot of progress, and that is resulting in newly diagnosed patients found every month.

Kalpit Patel
Analyst, Wolfe Research

Okay. And you also had separately a successful EXPAND study recently. We saw a benefit in the biliary atresia patients in that study. Previously, you mentioned that about 2,000 BA patients are there in the U.S. and across Europe. Are these patients already concentrated in the centers that you are calling on, and how straightforward is this expansion, or do you need to go out and find these patients, expand the sales force?

Eric Bjerkholt
CFO, Mirum

Good question. There is a very high level of overlap with our pediatric hepatologists, and that's because these patients, the biliary atresia patients, all get the Kasai procedure very early in life, so they're already identified. In total, we think with about 1,000 in the U.S., that would mean it's about the same number of patients as for Alagille syndrome. But the dosing is higher, and there shouldn't be any competition here. We think the opportunity is at least an Alagille syndrome.

Kalpit Patel
Analyst, Wolfe Research

Got it. Should we assume that the trajectory is a little faster than what we had seen with Alagille and PFIC historically?

Eric Bjerkholt
CFO, Mirum

I mean, you would think so based on what I've said, but we'll see.

Kalpit Patel
Analyst, Wolfe Research

Okay. Maybe Andrew, moving on to PSC. You clearly had a positive trial there, and one of the biggest questions that we get is the uncertainty on the regulatory path for PSC. The FDA had recommended another phase III despite your original trial hitting stat sig. Can you help us understand if anything has changed since your public announcement that the FDA is requiring or asking for another phase III? You presented some data at AASLD this past weekend. Anything from those subgroup analysis that should help drive confidence for this resubmission?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah. It's funny, we get that question a lot too. But effectively, there's no material update to provide and o ur conversations are progressing. Everything's on plan for a submission in the first half of next year. If something does come out of this interaction that is material or materially changes what we are planning on doing, then we'll tell you, b ut so far, so good. The IBD analysis, it's important to note that that was not in reaction to a question from the FDA recently. This was all part of the original design and plan.

So back in 2019, this was an area of focus for us and the FDA just to make sure that this is safe in patients with IBD since the majority of PSC patients have that. The analysis that we presented at AASLD shows that. So there's really no exacerbation. We did everything we could to assess that in the study, and I think it's a pretty reassuring analysis.

Kalpit Patel
Analyst, Wolfe Research

How directly do those analysis support what the FDA is asking for?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

I believe we've done all we can, and they would acknowledge that.

Kalpit Patel
Analyst, Wolfe Research

Okay. Moving beyond PSC, you are going to have data for PBC in the first quarter of 2027. How do you think about the opportunity there versus PSC, and what would be a clinically meaningful outcome in your view? I think historically you have mentioned about a 2-point placebo-adjusted delta, sample size gets bigger. Do you expect to see a 2-point delta again? What would drive clinical utilization in the real world as well?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah, something in that ballpark would be a win. I mean, obviously in the interim, we saw a greater than 2-point change, which we were very excited about. Also saw improvements in sleep and fatigue. We think both the magnitude of the clinical efficacy there and some of these benefits and broader measures of quality of life would translate into a really nice advantage commercially. Right now, I believe what is approved has a less than 1-point placebo-adjusted difference.

So, anything in the ballpark of what we saw at the interim would be a great win. And then to your other question on just the competitive difference between PBC and PSC, obviously PSC is, there is nothing approved, and so that is a kind of a wide open space for us, one that we are very excited about with the data set that we have. PBC, there is more competition, but it is a really large market and t here are over 80,000 patients. The majority of those have pruritus, and a large portion of those are in the frontline setting where they are well controlled on UDCA, so they are off-label for a PPAR, don't need it, but still have itch and t hat is a prime opportunity. Then beyond that, with PPARs, I think you still see opportunity there too, since those don't fully address the itching in a lot of patients.

Kalpit Patel
Analyst, Wolfe Research

Do you think the PBC safety outcome could be useful for the PSC filing, or is that not a gating factor for your submission?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Not a gating factor. I mean, it's obviously something the FDA will look at when they're looking at volixibat as a compound, but not a gating factor for us.

Kalpit Patel
Analyst, Wolfe Research

Okay. And how much confidence do you have for the PBC path relative to the PSC path?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

More. We've had breakthrough designation since 2024 after the interim analysis, so that's allowed us to have more interaction with the FDA. A lot of that back and forth is oriented towards recognition of this being a pivotal study, so feel much more confident about that.

Kalpit Patel
Analyst, Wolfe Research

Okay. I had one question on PSC for the trial population was a moderate to severe population. Do you expect utilization across the spectrum, broad spectrum of patients, or only in the moderate to severe population, assuming you get approval?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Across the spectrum. Grading pruritus is not something that is typically done in a physician's office. It is more of a clinical trial feature to ensure that you have a high enough baseline level of itch to measure a meaningful change. But typically, a physician is not asking a patient, "What's your itch on a scale of 0- 10?" It is more a question of, "Do you itch or not?" And that is how we would expect the label to be written, pruritus due to PSC or PBC.

Kalpit Patel
Analyst, Wolfe Research

What is the population size then across the spectrum of patients for the U.S.?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

We think there is about 50,000 patients, PBC patients with pruritus in the U.S., and about 20,000 or so PSC patients.

Kalpit Patel
Analyst, Wolfe Research

Got it. Maybe moving on to the hepatitis D part of this. A lot of data this past weekend. As you look through your own 24-week, 48-week, as well as the two-year experience that you have seen now, what have you learned that you did not originally appreciate from the AZURE-1 readout?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah, a lot of data this weekend. Very excited about it. I think the most important takeaway is that responses keep getting better over time. We designed our phase III's with a 24-week primary endpoint, which is mostly because you can see separation, statistically significant separation at that time, which is adequate to support a filing, so why do a longer study?

But as you follow these patients out to one year or two years, we see a really nice deepening of both virologic response in terms of TND, target not detected, and ALT normalization, which is a really important measure that goes along with it that I think gets missed, because what you want to do from a treatment objective perspective is suppress the virus, and ideally, you get rid of it, but t he other way to check that, given that your assays are not perfect, is to look at, is the inflammation gone? So if the virus is gone, you'd expect the inflammation to be gone, and we see that playing out over time and get to some really deep responses there.

Kalpit Patel
Analyst, Wolfe Research

Got it. And one of the most important questions we've been getting, or more frequent questions we've been getting is, people are looking at the TND rates and comparing, making cross-trial comparisons. VIR's dataset had a 79% TND at week 48% and 57% at week 24. And I think these are different studies, maybe the assays are different, but anything that you want to highlight that explains the differences between their TND rates and yours?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah, it's not apples- to- apples. There's differences in the baseline populations, which matter. If you look at our AZURE-4 data, which we just announced this morning, over half the patients had a six log HDV RNA level. And I think that's part of the challenge, is you talk about these things in logs, because a log scale, because the virus levels are so high. So that's basically about 1.2 million viral units per mL, which is a lot of virus. And if you compare that to a 5.4 log, for example, that's 200,000. So you're looking at how half the patients in the study had 4x the viral load as some of the other studies that are done.

So they've got a longer way to come down before they get to TND, and that's aside from differences in assays, right? These assays are all pretty sensitive, but at the end of the day, you are debating between 5 or 10 units per mL in terms of their sensitivity. These threshold analyses can kind of mask the fact that both therapies are getting patients to a great level of suppression. That is why you have to think about ALT, and if you are thinking about trying to get rid of the virus, how does that play into things?

Kalpit Patel
Analyst, Wolfe Research

Anything in the baseline demographics that you guys want to mention, differences between your study and their study?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

I mean, the viral loads is one, so significantly higher. ALT is also higher, about 30% higher.

Kalpit Patel
Analyst, Wolfe Research

What do you think—

Eric Bjerkholt
CFO, Mirum

Just interject that most people don't really think about logarithmic math, and the primary endpoint is a two-log reduction, which is a 99.9% reduction in the viral load. When we talk about LLOQ less than 10, that's a 99.98% reduction. It's important that people don't get too hung up on small differences in percentages when any agent that's going to get approved is going to show a really dramatic reduction in the viral load.

Kalpit Patel
Analyst, Wolfe Research

Across all the metrics in HDV, what do you think matters the most for physicians when they're evaluating a new therapy?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

It's a good question. I think that given how progressive this disease is, you really want to get the virus under control, and by extension, the inflammation. The inflammation is what causes cancer and some of these liver-related outcomes. So both of those pieces, getting those to very low levels or normal levels is critical and then maintaining that, right? You don't want to see viral rebound.

You want to see that improve over time. It's actually interesting, at AASLD this last weekend, the expert panel guidance around HDV treatment, the objective is to look for obviously as low as virus as you can get, so TND is the best standard that we have, and ALT normalization. If you can maintain that for 96 weeks, they recommend experimenting with treatment withdrawal. I think the key is the duration, right? You want to get this down low and suppressed and maintain that for as long as possible.

Kalpit Patel
Analyst, Wolfe Research

Got it. Have you looked at your samples and tested with the other assays, or are you planning to test it, make an apples- to- apples comparison?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

I mean, to Eric's point, no. Yeah, they're basically doing the same thing, and it doesn't really make a difference.

Kalpit Patel
Analyst, Wolfe Research

One of the more frequent questions we get also on hep D is that, are there really that many patients? These investors do doc calls, and they say hep D is very rare in the community, hard to find these patients. What do you say to these investors when you get pushback like that?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

I mean, we see a much different population. I mean, claims data supports that. These are patients who have multiple visits, under care, insured. I think the challenge when you call a physician in Boston is there's not a lot of hep D in Boston. You do see it concentrated in certain geographic centers, predominantly in community settings in these urban areas, so New York, Chicago, L.A. There's large communities there. You see some in Minnesota, for example, b ut it's not going to be picked up in your standard doc call per se.

Eric Bjerkholt
CFO, Mirum

They are not really in tertiary centers. They are much more in the community, and so you have to find community docs that are actually treating these patients.

Kalpit Patel
Analyst, Wolfe Research

Got it. Okay. You recently increased the peak sales guidance to a billion plus for hep D. Has anything over the past weekend changed the thinking around that $ 1 billion number?

Eric Bjerkholt
CFO, Mirum

No, no. I mean, the increase in guidance was driven more by HEPCLUDEX pricing, which was significantly higher than where the prior guidance, what the prior guidance was anchored on. So, our patient numbers have not really changed, although I noticed that Gilead came out recently and said there are 40,000- 80,000 patients, and here in their presentation yesterday or over the weekend said 61,000 or something like that. We are obviously being more conservative and trying to underpromise a little bit.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah, but we do see upside if testing increases, and currently there is very little testing that is done. I think less than 5%-10% of hep B patients are actually tested for hepatitis delta. So if you see that change, and I think the guidelines are moving towards that could find more too.

Kalpit Patel
Analyst, Wolfe Research

Do you guys think this is a chronic treatment, or is there a possibility of fixed duration treatment based on the results we're seeing from the past weekend?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

There's certainly a possibility for some patients. I think that would, if you talk to most physicians, that would be the ideal option, right, is a finite therapy. Frankly, that's the best thing for patients, so that makes sense. Right now, there's still questions to be answered about what that looks like and how to do it. I think they've taken a first step in their recommendations for maintaining TND and ALT normalization for about 96 weeks before you experiment with it. The data shows that you can have that, withdraw therapy, and then the virus rebounds. I think we still have some work to do there, but it's certainly, I think, a good objective.

Kalpit Patel
Analyst, Wolfe Research

The $1 billion peak sales does not assume a finite duration of treatment for your product?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

It assumes chronic therapy. I think that in a lot of these patients, you're going to have at least multiple years of therapy before even in some you get to a treatment, so—

Kalpit Patel
Analyst, Wolfe Research

Can you talk about the decision to go for once-weekly regimen versus once monthly? I think the data zooming out seemed to be pretty similar, at least when you go and expand into longer durations of treatment. Just curious on the thinking there.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah, the feedback that we've had from a commercial perspective is the once weekly is much more convenient and preferred for that reason. I mean, I think there's some debate on it. I mean, obviously you can have patients that would prefer once monthly, but by and large, we think the once weekly will be the better option.

Kalpit Patel
Analyst, Wolfe Research

You posted data for AZURE-4 today. Talk to us about those results. Anything different versus AZURE-1 that you want to highlight?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Not really. It's very consistent, other than some of the baseline characteristics that I mentioned earlier in terms of baseline viral loads. Data consistent, no new safety signals, so we're on track to file our BLA in the first half of next year. Very excited to move this forward. Just as a reminder, AZURE-1 and AZURE-4 were the two studies needed to support the BLA package.

Kalpit Patel
Analyst, Wolfe Research

Got it. The $1 billion+ peak sales expectation you have, is that U.S. plus Europe or is that U.S. only?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Global.

Kalpit Patel
Analyst, Wolfe Research

Global. Okay. Got it. Moving on to FOP, I wanted to touch on the patients there, your initial launch expectations following September's approval. You've had, I think you've mentioned recently, you've had strong engagement with prescribers. There could be stronger adoption than LIVMARLI's original launch. What gives you that confidence? Is it the concentration of the known patients, the severity of the disease, or anything else that you're expecting a strong launch there?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah, I'd say both of those. So it's a very severe disease, patients are well identified, and we have a therapy that is really impactful. So all three of those factors we think would support a different launch profile than what we saw with LIVMARLI.

Eric Bjerkholt
CFO, Mirum

It's a highly engaged patient community. Just to give you an anecdote, the day we got approved, overnight we got a congratulatory email from a family in Turkey. So, this is a patient population and the families that are really paying attention and are really desperate for new treatment options.

Kalpit Patel
Analyst, Wolfe Research

Got it. The $10 million-$15 million sequential growth that you guys cited on the third quarter earnings, does that include contribution from the EXPAND study from this launch? What exactly does that $10 million to $15 million include?

Eric Bjerkholt
CFO, Mirum

Yeah, it is meant to be for the portfolio overall. To be clear, I mean, we just wanted to put that out there so people could have some sense of where we are headed. But as usual, in early January, we will be pre-announcing revenues for the year and also give more specific guidance for revenues for 2027.

Kalpit Patel
Analyst, Wolfe Research

Okay. Do you guys expect to be positive cash flow next year, operating cash flow?

Eric Bjerkholt
CFO, Mirum

Absolutely, yes. I mean, we were cash flow positive last year. We were cash flow positive first half of this year. But as we have signaled, because of the somewhat heavy R&D lift driven by brelovitug for both clinical studies as well as manufacturing, we expect it to be somewhat cash flow negative in the second half. In the third quarter, it was $-4 million. So not a lot, but a little bit. But we absolutely expect to return to be cash flow positive next year.

Kalpit Patel
Analyst, Wolfe Research

Talk to us about the spending trajectory. You had some temporary phase III increases as well as OpEx increases, as well as for manufacturing activity. How much of that should we expect to replicate in 2027?

Eric Bjerkholt
CFO, Mirum

Yeah. So let me give you kind of the, again, the big picture. So the commercial cash contribution margin has been in the high 50s percent for the last few quarters. We expect it to continue at that level, but once we get more revenue and new medicines launched, that will expand well past 60%. On the R&D side, because of this heavy lift, it's been about 50% of revenues, but will trail down significantly over the Probably stay at that level another quarter or two, but then after that, really trail down quite significantly as a percent of revenue. Then for kind of non-commercial G&A is also trailing down as a percent of revenue.

Kalpit Patel
Analyst, Wolfe Research

Andrew, how should we think about additional BD activity versus just monetizing what you have in the pipeline today? Historically, you guys do a lot of transactions, so curious to hear what's next.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah. Well, I mean, I think just kind of going back to where Eric started, only 5% of orphan diseases have an approved therapy, so there's a lot of opportunity out there for us. Our team is always active. We're always looking. I think that's coupled with a lot of discipline. We have a high bar for bringing something in. It has to make sense for us to be the owners of it, has to be transactable, has to make sense financially and w e've got a lot of great things in the portfolio, so that gives us the luxury of being able to be disciplined.

Kalpit Patel
Analyst, Wolfe Research

Got it. Okay. Andrew, if we were having this conversation another year from now, what are two or three milestones that you want to highlight that would demonstrate that Mirum is a successful company in transitioning from a small rare disease company into a multi-billion dollar franchise?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Yeah, I mean, I think continuing on the trajectory that we've been on and getting all these medicines I talked about approved, brelovitug, volixibat in two indications, the sNDA for the EXPAND study in biliary atresia, younger population approved for ATEBRIOZ. We think we can achieve all of that, and that's our goal, and we want to be held accountable to achieving all of that. That's going to really benefit patients and expanding patient populations, take us into much larger patient populations, and that will, from a business standpoint, result in very strong revenue growth for many years, and as I said, also generate a lot of cash for investors.

Kalpit Patel
Analyst, Wolfe Research

Okay. That's all I have. Anyone in the audience has any questions for the team? Happy to take questions. Once? Okay. Well, thank you.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum

Thanks for having us.

Eric Bjerkholt
CFO, Mirum

Thanks for having us.